Literature DB >> 28214059

Pharmacokinetic alterations of rhubarb anthraquinones in experimental colitis induced by dextran sulfate sodium in the rat.

Wen-Jin Wu1, Ru Yan1, Ting Li1, Ya-Ping Li1, Rui-Na Zhou1, Yi-Tao Wang1.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Rhubarb (Rhei Rhizoma et Radix) is used for the treatment of digestive diseases in traditional medicinal practice in China. Recent studies also support its beneficial activities in alleviating ulcerative colitis (UC). AIM OF THE STUDY: This study aimed to characterize the oral pharmacokinetics of rhubarb anthraquinones, the main bioactive components of this herb, in the experimental chronic colitis rat model induced by dextran sulfate sodium (DSS) and to identify the factors causing the pharmacokinetic alterations.
MATERIALS AND METHODS: Rats received drinking water (normal group) or 5% DSS for the first 7 days and 3% DSS for additional 14 days (UC group). On day 21 both groups received an oral dose of the rhubarb extract (equivalent to 5.0g crude drug/kg body weight). Plasma anthraquinone aglycones levels were determined directly by an LC-MS/MS method and the total of each anthraquinone (aglycone+conjugates) was quantified after β-glucuronidases hydrolysis.
RESULTS: Rhubarb anthraquinones predominantly existed as conjugates in plasma samples from both groups and only free aloe-emodin, rhein and emodin were detected. Compared to the normal rats, both Cmax and AUC of the three free anthraquinones were increased, while the systemic exposure (AUC) of the total (aglycone+conjugates) of most anthraquinones decreased by UC accompanied by the disappearance of multiple-peak phenomenon in the plasma concentration-time profiles. Gut bacteria from UC rats exhibited a decreased activity in hydrolyzing anthraquinone glycosides to form respective aglycone and there were significant decreases in microbial β-glucosidases and β-glucuronidases activities. Moreover, the intestinal microsomes from UC rats catalyzed glucuronidation of free anthraquinones with higher activities, while the activities of hepatic microsomes were comparable to normal rats.
CONCLUSIONS: The decreases of β-glucuronidases activity in DSS-induced chronic rat colitis should mainly account for the decreases in systemic exposure and abrogation of enterohepatic recirculation of most rhubarb anthraquinones after oral intake.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28214059     DOI: 10.1016/j.jep.2017.01.049

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

1.  High-resolution MS/MS metabolomics by data-independent acquisition reveals urinary metabolic alteration in experimental colitis.

Authors:  Zhixiang Yan; Ting Li; Bin Wei; Panpan Wang; Jianbo Wan; Yitao Wang; Ru Yan
Journal:  Metabolomics       Date:  2019-04-30       Impact factor: 4.290

2.  A UPLC-MS/MS method for simultaneous quantification of pairs of oleanene- and ursane-type triterpenoid saponins and their major metabolites in mice plasma and its application to a comparative pharmacokinetic study.

Authors:  Wenwen Zhao; Zongyang Liu; Weiwei Guo; Kui Luo; Jie Yang; Wei Gao; Xia Wu; Xiaoqing Chen
Journal:  RSC Adv       Date:  2018-02-26       Impact factor: 4.036

3.  Panax notoginseng Promotes Repair of Colonic Microvascular Injury in Sprague-Dawley Rats with Experimental Colitis.

Authors:  Shiying Wang; Ping Tao; Lei Zhao; Wangjun Zhang; Hongyi Hu; Jiang Lin
Journal:  Evid Based Complement Alternat Med       Date:  2018-01-29       Impact factor: 2.629

Review 4.  Pharmacokinetics of Anthraquinones from Medicinal Plants.

Authors:  Dongpeng Wang; Xian-He Wang; Xiongjie Yu; Fengjun Cao; Xiaojun Cai; Ping Chen; Minglun Li; Yibin Feng; Hongliang Li; Xuanbin Wang
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 5.  Pharmacokinetics of Chinese medicines: strategies and perspectives.

Authors:  Ru Yan; Ying Yang; Yijia Chen
Journal:  Chin Med       Date:  2018-05-02       Impact factor: 5.455

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.